Alembic Pharmaceuticals share price climbs after USFDA green light for Carbamazepine ER

Market performance

• Alembic Pharmaceuticals share price was ₹1,010.50 at 09:21 am, up ₹12.20 (1.22%) on the BSE.
• 52-week high: ₹1,296.15 (9 October 2024)
• 52-week low: ₹725.60 (3 March 2025)
• The stock is 22.04% below its 52-week high and 39.26% above its 52-week low.
• Market cap: ₹19,862.70 crore.

Main news

Alembic Pharmaceuticals stated that it has obtained final approval from the USFDA for its Carbamazepine Extended-Release Tablets USP available in strengths of 100 mg, 200 mg, and 400 mg.

• The cleared ANDA is therapeutically equivalent to Tegretol‑XR (100 mg, 200 mg, 400 mg) of Novartis Pharmaceuticals Corporation.
• Use case: Carbamazepine is prescribed as an anticonvulsant and for pain linked to true trigeminal neuralgia.

Company details

• Total ANDA tally: 225 approvals — 202 final and 23 tentative.
• Board meet: August 5, 2025, to consider unaudited Q1 FY26 (quarter ended June 30, 2025) results.
• Credit profile: CRISIL Ratings reaffirmed AA+/Stable on bank loan facilities with enhanced limits of ₹800 crore.
• Leadership move: Dr. Sachin Ghosalkar appointed Sr. Vice President – SCM & Operations, effective July 21, 2025.

Summary

The Alembic Pharmaceuticals share price moved higher after the company received the USFDA’s final nod for Carbamazepine ER tablets. With 225 ANDA approvals, a forthcoming August 5 board meeting, a reaffirmed AA+/Stable rating, and a new senior operations leader, the latest updates keep Alembic Pharmaceuticals share price in focus for investors tracking regulatory milestones and corporate developments.